Cargando…

The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1

PD-L1 has been characterized as an inhibitory immune checkpoint, leading to the suppression of potential anti-tumor immune activities in many cancer types. In view of the relatively limited efficacy of immune checkpoint blockades against PD-L1 in breast cancer, our recent study addressed the possibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Erlichman, Nofar, Meshel, Tsipi, Baram, Tamir, Abu Raiya, Alaa, Horvitz, Tamar, Ben-Yaakov, Hagar, Ben-Baruch, Adit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571791/
https://www.ncbi.nlm.nih.gov/pubmed/37830552
http://dx.doi.org/10.3390/cells12192338
_version_ 1785120084152287232
author Erlichman, Nofar
Meshel, Tsipi
Baram, Tamir
Abu Raiya, Alaa
Horvitz, Tamar
Ben-Yaakov, Hagar
Ben-Baruch, Adit
author_facet Erlichman, Nofar
Meshel, Tsipi
Baram, Tamir
Abu Raiya, Alaa
Horvitz, Tamar
Ben-Yaakov, Hagar
Ben-Baruch, Adit
author_sort Erlichman, Nofar
collection PubMed
description PD-L1 has been characterized as an inhibitory immune checkpoint, leading to the suppression of potential anti-tumor immune activities in many cancer types. In view of the relatively limited efficacy of immune checkpoint blockades against PD-L1 in breast cancer, our recent study addressed the possibility that in addition to its immune-inhibitory functions, PD-L1 promotes the pro-metastatic potential of the cancer cells themselves. Indeed, our published findings demonstrated that PD-L1 promoted pro-metastatic functions of breast cancer cells in a cell-autonomous manner, both in vitro and in vivo. These functions fully depended on the integrity of the S283 intracellular residue of PD-L1. Here, using siRNAs and the S283A-PD-L1 variant, we demonstrate that the cell-autonomous pro-metastatic functions of PD-L1—tumor cell proliferation and invasion, and release of the pro-metastatic chemokine CXCL8—required the activation of STAT3 and STAT1 in luminal A and triple-negative breast cancer cells. The cell-autonomous pro-metastatic functions of PD-L1 were potently impaired upon inhibition of N-linked glycosylation (kifunensine). Site-specific mutants at each of the N-linked glycosylation sites of PD-L1 (N35, N192, N200, and N219) revealed that they were all required for PD-L1-induced pro-metastatic functions to occur; the N219 site was the main regulator of STAT3 and STAT1 activation, with accompanying roles for N192 and N200 (depending on the cell type). Using a T cell-independent mouse system, we found that cells expressing N35A-PD-L1 and N219A-PD-L1 had a significantly lower tumorigenic and metastatic potential than cells expressing WT-PD-L1. TCGA analyses revealed significant associations between reduced survival and high levels of α-mannosidase II (inferring on N-linked glycosylation) in breast cancer patients. These findings suggest that N-linked glycosylation of PD-L1 may be used to screen for patients who are at greater risk of disease progression, and that modalities targeting N-linked glycosylated PD-L1 may lead to the inhibition of its cell-autonomous pro-metastatic functions and to lower tumor progression in breast cancer.
format Online
Article
Text
id pubmed-10571791
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105717912023-10-14 The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1 Erlichman, Nofar Meshel, Tsipi Baram, Tamir Abu Raiya, Alaa Horvitz, Tamar Ben-Yaakov, Hagar Ben-Baruch, Adit Cells Article PD-L1 has been characterized as an inhibitory immune checkpoint, leading to the suppression of potential anti-tumor immune activities in many cancer types. In view of the relatively limited efficacy of immune checkpoint blockades against PD-L1 in breast cancer, our recent study addressed the possibility that in addition to its immune-inhibitory functions, PD-L1 promotes the pro-metastatic potential of the cancer cells themselves. Indeed, our published findings demonstrated that PD-L1 promoted pro-metastatic functions of breast cancer cells in a cell-autonomous manner, both in vitro and in vivo. These functions fully depended on the integrity of the S283 intracellular residue of PD-L1. Here, using siRNAs and the S283A-PD-L1 variant, we demonstrate that the cell-autonomous pro-metastatic functions of PD-L1—tumor cell proliferation and invasion, and release of the pro-metastatic chemokine CXCL8—required the activation of STAT3 and STAT1 in luminal A and triple-negative breast cancer cells. The cell-autonomous pro-metastatic functions of PD-L1 were potently impaired upon inhibition of N-linked glycosylation (kifunensine). Site-specific mutants at each of the N-linked glycosylation sites of PD-L1 (N35, N192, N200, and N219) revealed that they were all required for PD-L1-induced pro-metastatic functions to occur; the N219 site was the main regulator of STAT3 and STAT1 activation, with accompanying roles for N192 and N200 (depending on the cell type). Using a T cell-independent mouse system, we found that cells expressing N35A-PD-L1 and N219A-PD-L1 had a significantly lower tumorigenic and metastatic potential than cells expressing WT-PD-L1. TCGA analyses revealed significant associations between reduced survival and high levels of α-mannosidase II (inferring on N-linked glycosylation) in breast cancer patients. These findings suggest that N-linked glycosylation of PD-L1 may be used to screen for patients who are at greater risk of disease progression, and that modalities targeting N-linked glycosylated PD-L1 may lead to the inhibition of its cell-autonomous pro-metastatic functions and to lower tumor progression in breast cancer. MDPI 2023-09-23 /pmc/articles/PMC10571791/ /pubmed/37830552 http://dx.doi.org/10.3390/cells12192338 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Erlichman, Nofar
Meshel, Tsipi
Baram, Tamir
Abu Raiya, Alaa
Horvitz, Tamar
Ben-Yaakov, Hagar
Ben-Baruch, Adit
The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
title The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
title_full The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
title_fullStr The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
title_full_unstemmed The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
title_short The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
title_sort cell-autonomous pro-metastatic activities of pd-l1 in breast cancer are regulated by n-linked glycosylation-dependent activation of stat3 and stat1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571791/
https://www.ncbi.nlm.nih.gov/pubmed/37830552
http://dx.doi.org/10.3390/cells12192338
work_keys_str_mv AT erlichmannofar thecellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT mesheltsipi thecellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT baramtamir thecellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT aburaiyaalaa thecellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT horvitztamar thecellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT benyaakovhagar thecellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT benbaruchadit thecellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT erlichmannofar cellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT mesheltsipi cellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT baramtamir cellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT aburaiyaalaa cellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT horvitztamar cellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT benyaakovhagar cellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1
AT benbaruchadit cellautonomousprometastaticactivitiesofpdl1inbreastcancerareregulatedbynlinkedglycosylationdependentactivationofstat3andstat1